中文摘要：

芬戈莫德（FTY720）作为一种新型免疫抑制剂，是第1种被美国食品药品监督管理局（FDA）批准用于治疗复发缓解型多发性硬化（RRMS）的一线口服药物。此外，FTY720在治疗胶质母细胞瘤（GBM）的体内和体外实验中也表现出有效的抗癌作用。本文就FTY720在抗GBM中所发挥的作用及其机制研究进展作一综述。

英文摘要：

Fingolimod （FTY720） as a new immunosuppressive agent, is the prodrug of an sphingosine -1-phosphate receptor agnnist. It is a potent immunosuppressant which has been approved by the US Food and Drug Administration to treat relapsing-remitting multiple sclerosis, and shows its unique and novel mechanism of action. Unlike the traditional immunosuppressive agents, fingolimod exerts immunosuppressive and immunoregnlatory functions mainly through interaction with shhingosine-1-phosphate receptors on the cell surface without affecting activation and proliferation of lymphocytes. In addition, FTY720 has been shown to inhibit a variety of cancer related signal transduction pathways. It also presented significant anticancer effects in the in vivo and in vitro experiments. And in the treatment of glioblastoma multiforme （GBM） experiment, FTY720 displayed excellent activity as well had a synergistic effect in addition to temozolomid, the current standard chemotherapeutic agent to treat malignant gliomas. This article reviewed the advances in study on the anti-GBM effect and mechanism of FTY720.